About Olfactory receptor 1L1
Olfactory receptor 1L1 (OR1L1) is a protein
from Homo sapiens identified by UniProt accession
Q8NH94, 360 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Olfactory receptor 1L1 |
|---|
| UniProt accession | Q8NH94 |
|---|
| Gene | OR1L1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 360 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (10)
Diseases linked to this target (Open Targets).
- neuroblastoma · score 0.21
- chronic lymphocytic leukemia · score 0.18
- clear cell renal carcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- fasting blood glucose measurement · score 0.12
- fasting blood insulin measurement · score 0.12
- HOMA-B · score 0.12
- lymphocyte percentage of leukocytes · score 0.03
- body height · score 0.02
- pulse pressure measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NH94-F1 | alphafold | PREDICTED | 81.40 | — |
Amino-acid sequence (360 residues)
MERNHNPDNC NVLNFFFADK KNKRRNFGQI VSDVGRICYS VSLSLGEPTT MGRNNLTRPS EFILLGLSSR PEDQKPLFAV FLPIYLITVI GNLLIILAIR SDTRLQTPMY FFLSILSFVD ICYVTVIIPK MLVNFLSETK TISYSECLTQ MYFFLAFGNT DSYLLAAMAI DRYVAICNPF HYITIMSHRC CVLLLVLSFC IPHFHSLLHI LLTNQLIFCA SNVIHHFFCD DQPVLKLSCS SHFVKEITVM TEGLAVIMTP FSCIIISYLR ILITVLKIPS AAGKRKAFST CGSHLTVVTL FYGSISYLYF QPLSNYTVKD QIATIIYTVL TPMLNPFIYS LRNKDMKQGL AKLMHRMKCQ
Explore Olfactory receptor 1L1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets